CN1325071C - Antiphlogistic medicine - Google Patents
Antiphlogistic medicine Download PDFInfo
- Publication number
- CN1325071C CN1325071C CNB2005100487329A CN200510048732A CN1325071C CN 1325071 C CN1325071 C CN 1325071C CN B2005100487329 A CNB2005100487329 A CN B2005100487329A CN 200510048732 A CN200510048732 A CN 200510048732A CN 1325071 C CN1325071 C CN 1325071C
- Authority
- CN
- China
- Prior art keywords
- inflammation
- antiphlogistic medicine
- medicine
- group
- antiphlogistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides antiphlogistic medicine characterized in that the antiphlogistic medicine is prepared from the following raw materials of one to six portions of spatholobus stem, three to ten portions of caesalpinia, two to eight portions of plant soot, and one to three portions of borneol. The antiphlogistic medicine has the effects for clearing away heat and toxic materials, strengthening throats, relieving inflammation, relaxing pain, dispelling wind, eliminating dampness, activating blood, dissolving stasis, resolving turbidity, removing dampness, relieving itch, astringing, promoting tissue regeneration, etc. The antiphlogistic medicine has peculiar effects on detoxification, inflammation relieving, analgesia, hemostasis, itch relieving, etc. The antiphlogistic medicine does not have poison or side effects. When the antiphlogistic medicine is orally taken, the antiphlogistic medicine can treat the inflammation on upper respiratory tracts, such as stomatitis, pharyngitis, tonsillitis, tracheitis, etc., the gastroenteritis, such as cholecystitis, gastritis, enteritis, etc., and the inflammation, such as cystitis, urethritis, pelvic inflammation, hemorrhoid, etc. When the antiphlogistic medicine is externally used, the antiphlogistic medicine can treat cutaneous pruritus, tinea of feet and hands, dermatoneuritis, herpes zosters, eczema, burn, traumatic bleeding, wound infection, etc. The antiphlogistic medicine has the advantages of favorable curative effect and wide popularization.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, especially a kind of All Pure Nature Chinese herbal medicine preparation that can antiinflammatory belongs to biological technical field.
Background technology
Whenever people because of various inflammation as upper respiratory tract infection such as pharyngitis, tracheitis, tonsillitis and pneumonia, alimentary canal inflammations such as gastritis, enteritis and cholecystitis, wing light inflammation, urethritis, pelvic inflammatory disease and gynecological inflammation need be taken medicine and be cured or when going to see a doctor, mostly use Western medicine such as universal antibiotic, but it is well-known, though these antibiotics instant effects, good effect, but exist the big serious problems of toxic and side effects, to this, domestic have strict restriction to antibiotic use especially abroad.Chinese medicine is the traditional medicine of China, has unique effect, and toxic and side effects is less relatively, but various anti-inflammatory type Chinese herbal and crude drugs preparationses in the market, only limit to treat certain single inflammation, and curative effect is not too obvious, can only use as auxiliary medicaments, does not reach the antiinflammation of universal far away.Therefore, be necessary to excavate the marrow in China's medical treasure-house fully, the Chinese medicine preparation with universal antiinflammation of development and exploitation special effect reaches the medical science aim of curing the sickness to save the patient.
Summary of the invention
For overcoming the deficiency of prior art, satisfy the healthy demand of people, the invention provides a kind of special effect, have no side effect, have the anti-inflammation drugs of universal.
Anti-inflammation drugs provided by the invention is made up of the raw material of following mass parts:
Caulis Spatholobi 1-6 part
Semen Caesalpiniae Minacis 3-10 part
Pulvis Fumi Carbonisatus 2-8 part
Borneolum Syntheticum 1-3 part.
Wherein, its nature and flavor of Caulis Spatholobi are arduous, cool, go into the heart, lung meridian, can lead to all keys, and the stagnated fire of loosing makes eye bright, and reducing swelling and alleviating pain is used for the treatment of the apoplexy locked mouth, calentura coma, deafness with qi stagnation, aphtha, diseases such as otitis media; Semen Caesalpiniae Minacis has another name called Semen Caesalpiniae Minacis, crow medicated pillow, its nature and flavor hardship, cold, go into the heart, spleen, kidney three warps, have dissipating blood stasis, pain relieving, clearing heat and removing internal wetness, an effect such as the relieving restlessness of whetting the appetite, clear away heart-fire, can control dysentery, stranguria with turbid discharge, hematuria, traumatic injury, diseases such as skin infection among the peoplely are usually used in treating influenza; Its nature and flavor suffering of Pulvis Fumi Carbonisatus, temperature are gone into liver, lung, stomach warp, have hemostasis, the heat clearing away repercussive, and effects such as removing food stagnancy can be controlled haematemesis, have blood in stool metrorrhagia, leukorrhagia, dysentery, food stagnation, diseases such as all skin ulcers of throat dispute; Its nature and flavor of Borneolum Syntheticum are arduous, cool, go into the heart, spleen channel, have invigorate blood circulation, the effect of Shujin, can control soreness of waist and knee joint, paralysis and numbness, menoxenia can blood stasis removing blood, tissue regeneration promoting blood.Behind their mutual compatibilities, has unique effects at detoxifcation, antiinflammatory, analgesia, hemostasis, aspect such as antipruritic.
The present invention adopts following method to make: after described raw material powder is broken into powder, with prior art tablet forming system or make pill, pill or the softgel shell of packing into is made capsule and got final product.
The present invention compared with prior art has following advantage and effect: adopt such scheme, make product have heat-clearing and toxic substances removing, sore-throat relieving, anti-inflammatory analgesic, the dispelling wind damp eliminating, blood circulation promoting and blood stasis dispelling, resolving turbidity and eliminating dampness, eliminating stagnation is antipruritic, effects such as convergence granulation promoting, especially in detoxifcation, antiinflammatory, analgesia, hemostasis, aspect such as antipruritic has unique effects, and the present invention all adopts the pure natural Chinese herbal medicine to make, and is nontoxic, have no side effect, and raw material is easy to get, and can make acceptable any preparation, both oral administration according to market demand, but external again, take orally and can treat stomatitis, pharyngitis, tonsillitis, upper respiratory tract infection such as tracheitis, cholecystitis, gastritis, gastrointestinal inflammations such as enteritis, cystitis, urethritis, pelvic inflammatory disease, inflammation such as hemorrhoid, external can be treated skin pruritus, tinea manus and pedis, neural dermatitis, herpes zoster, eczema, burn, disease such as traumatic hemorrhage and wound infection, be a good effect in fact, the anti-inflammation drugs that universal is strong.
For showing the present invention's curative effect, the present invention is through pharmacodynamics test, and its result is as follows:
One. medicament sources: Pan family's black powder that Yingjiang County, Yunnan Province Mr. Pan Zhengguo provides.
Two. supply the medicine time: November 20 calendar year 2001
Three. medicine lot number: 01120
Four. experimental animal: rabbit 2.1-2.5kg; Rat 120-150g; Mice 20-22g
Five. method and result:
1, hemostasis experiment: test adopts slide method to measure the clotting time of rabbit.
Get 9 of rabbit, be divided into 3 groups.One group is the blank group, does not give any medicine; Two groups give Pan family's black powder by 20mg/kg body weight and 40mg/kg body weight filling stomach respectively in addition.Cut with the knife blade vein of respectively each rabbit one being picked up the ears behind the 1h, get blood one big dripping and place on the microscope slide.After two minutes, every half a minute with dry syringe needle provoke on the microscope slide blood once, till seeing fiber protein yarn.The record autoblood flows out to the time that fiber protein yarn occurs, is clotting time.Then medication group and blank group are compared.
The result: the blank group is: 10.3+0.8min; The 20mg/kg group is: 7.6-0.5min; The 40mg/kg group is: 5.8-0.3min.
The result shows that Pan family's black powder has the effect of tangible shortening clotting time, shows that it has anastalsis preferably, and acts on enhancing with the dosage increasing.
2, antiinflammatory test: test employing Ovum Gallus domesticus album causes the fat bloated method of rat foot to carry out.
Get 20 of rats, be divided into two groups, one group of another group of administration is for blank.At first use 10% fresh Ovum Gallus domesticus album in each Mus left side toes subcutaneous injection 0.1ml during test, administration group subsequently is in Pan family's black powder of injection site coating 40mg/ml concentration, measure toes swelling degree respectively at 10min, 30min, 1h, 2h, 4h, 6h with tape then, and carry out parallel comparison two groups.
The result is respectively: matched group 0.8+0.05cm, 1.4+0.03cm, 1.8+0.03cm, 1.8+0.05cm, 1.6+0.04cm, 1.5+0.04cm; Administration group 0.8+0.04cm, 1.1+0.05cm, 1.3+0.04cm, 1.2+0.03cm, 1.0+0.03cm, 0.7+0.03cm.
The result shows, Pan family's black powder can obviously suppress the rat paw edema that caused by adjuvant Ovum Gallus domesticus album, shows to have certain antiinflammatory action.
3, bacteriostatic test: test adopts dull and stereotyped bacteriostatic method to carry out
By dull and stereotyped bacteriostatic test requirement, adopt broth bouillon, paper disk method carries out.Strain is selected staphylococcus aureus, escherichia coli, bacillus pyocyaneus, streptococcus pneumoniae for use; Drug level is respectively 10ug/ sheet, 20ug/ sheet, 80ug/ sheet, 160ug/ sheet, observes each scraps of paper inhibition zone size on every side behind 37 ℃ of cultivation 10h.
The result shows that Pan family's black powder has certain inhibitory action to above-mentioned strain.When scraps of paper concentration reached 80ug, inhibition zone was all more than 10mm.
4, inhibition test: test adopts infection S180 method to carry out
Get 30 of male mices, respectively at right side internal organs nest subcutaneous vaccination S180 cell suspension 0.2ml; Inoculation back next day is divided into 3 groups at random with mice, and one group is blank, and irritate stomach respectively and give Pan family's black powder 20mg/kg body weight and 40mg/kg body weight for two groups in addition, once a day, successive administration 10 days; After the drug withdrawal the 3rd day, put to death animal, claim each Mus body weight earlier, dissect the subcutaneous tumors piece subsequently, and weigh one by one, heavy according to each group tumor at last, compare with the blank group respectively, to judge the inhibitory action of medicine to the growth of S180 sarcoma.
The result: blank group tumor heavily is: 3.8+0.4g; 20mg/kg group tumor heavily is: 2.8+0.4g; 40mg/kg group tumor heavily is: 2.3+0.4g, tumour inhibiting rate are respectively 26.32% and 39.48%
The result shows that Pan family's black powder has certain inhibitory action to the growth of S180 sarcoma.Especially the 40mg/kg group acts on comparatively obvious.
5, raise immunity: test employing mice carbon is cleaned up method and is carried out
Get 30 of mices, be divided into 3 groups, one group is blank group, irritates stomach respectively and gives Pan family's black powder 20mg/kg body weight and 40mg/kg body weight for two groups in addition.Once a day, continuous 7 days, 1h after the last administration, respectively at each caudal vein injection colloidal-carbon suspension 0.1mg/kg body weight, use every 3min subsequently and get blood with the suction pipe of the moistening mistake of heparin solution through the eye rear vein beard in advance, each 0.025ml, continuous get blood 5 times after, the blood adding is filled in vitro shaking up of 1ml distilled water, in spectrophotometer 600mm wavelength place record trap, put to death mice at last, get liver respectively, spleen is weighed, and heavily wait factor to calculate the activate the phagocytic capacity of per unit tissue weight according to different traps, liver, spleen.
The result shows that Pan family's black powder has stronger activate the phagocytic capacity, shows that it has the enhancing human body immunity function.
Through 497 routine clinical observations, its result is as follows again in the present invention:
One, data and method
1, physical data
Tangible stomatitis is arranged, pharyngitis, tonsillitis, patient 108 people of upper respiratory tract infection such as tracheitis have tangible cholecystitis, gastritis, alimentary canal inflammation patient 86 people that enteritis etc. are made a definite diagnosis through local hospital, tangible cystitis is arranged, urethritis, pelvic inflammatory disease is also made a definite diagnosis its patient that these lower respiratory tract inflammation are arranged 115 people through local hospital, tangible skin pruritus is arranged, tinea manus and pedis, neural dermatitis, patient 100 people of herpes zoster, burn, Serpentis, insect bite, traumatic injury is hindered, patient's 88 examples of traumatic hemorrhage and wound infection.The above-mentioned object of observation is divided into two groups at random, and two groups of patients' ordinary circumstance sees table 1, table 2, table 3, table 4 and table 5 for details.
2, Therapeutic Method
The upper respiratory tract infection matched group is taken commercially available Radix Isatidis tablet, and instructions of taking and dosage are taken by its description is described.
The cholecystitis matched group is taken commercially available cholagogic tablet, and instructions of taking and dosage are described by its description.
The gastroenteritis matched group is taken commercially available the intestines and stomach relieving capsule, and instructions of taking and dosage are described by its description.
Lower respiratory tract inflammation matched group is taken commercially available SHUMITONG JIAONANG, and instructions of taking and dosage are described by its description.
Dermatitis, skin pruritus, tinea manus and pedis matched group use commercially available dermatitis plaster, and using method and dosage are described by its description.
Burning, snakebite, traumatic hemorrhage and wound infection matched group are coated with uses commercially available external-applied ointment, and using method and dosage are described by its description.
The treatment group is all used capsule provided by the invention, and three times on the one, each 3-5 grain.
Other related drugs all takes, and cut out to matched group for two groups with test group during treating by the identical course of treatment.
3, observational technique
Period in a medicine is observed weekly once, comprises symptom, sign improvement situation, untoward reaction.Have a blood test respectively pressure, urine, stool and routine blood test regulating liver-QI, renal function before and after the treatment.
Two, curative effect judgment criteria
1, criterion of therapeutical effect
According to the criterion of therapeutical effect of Ministry of Public Health bureau of drug administration about " the clinical research guideline of new drug (Chinese medicine) treatment " regulation.
Cure: the symptom complete obiteration, every index drops to normal value;
Produce effects: clinical cardinal symptom obviously alleviates, and every index drops near normal value;
Effectively: cardinal symptom alleviates, and every index has been fallen more than 50%;
Invalid: symptom alleviates to some extent, and every index does not descend.
2, statistical method
Enumeration data adopts X
2The t check is adopted in check, measurement data.
Total effective rate=cure rate+obvious effective rate+effective percentage
Three, result
1, upper respiratory tract infection improvement situations such as stomatitis, pharyngitis, tonsillitis, tracheitis see Table 6.
2, alimentary canal inflammation improvement situations such as cholecystitis, gastritis, enteritis see Table 7.
3, lower respiratory tract inflammation improvement situations such as cystitis, urethritis, prostate see Table 8.
4, skin pruritus, tinea manus and pedis, neural dermatitis, herpes zoster improvement situation see Table 9.
5, scald, snakebite, traumatic hemorrhage and wound infection improvement situation see Table 10.
6, untoward reaction
Treatment group patient has no adverse reaction, and laxativeness appears in individual patient, promptly ends after the drug withdrawal.The matched group patient has symptom in various degree such as xerostomia, scorching, constipation.
Four, discuss
Because the present invention all adopts natural pure Chinese medicine medical material to make, when diminishing inflammation, also have conditioning, the effect of balance body, the back of taking medicine is nontoxic, untoward reaction such as have no side effect, wound body not, do not get angry, take medicine and do not have taboo, human body is had the immunity of increasing, important function such as disease-resistant, extremely the patient likes in the locality, difficult inflammation also there is therapeutic effect, and instant effect, lasting, the curative effect mystery.
The specific embodiment
Below in conjunction with embodiment the present invention is described further.
Embodiment 1
Get material by following proportioning:
3 kilograms of 1 kilogram of Semen Caesalpiniae Minaciss of Caulis Spatholobi
3 kilograms of 8 kilograms of Borneolum Syntheticums of Pulvis Fumi Carbonisatus
Above-mentioned raw materials is ground into powder successively, is pressed into 50000 in the tablet of every 0.3g with prior art.
Embodiment 2
Get material by following proportioning:
10 kilograms of 6 kilograms of Semen Caesalpiniae Minaciss of Caulis Spatholobi
1 kilogram of 2 kilograms of Borneolum Syntheticum of Pulvis Fumi Carbonisatus
Above-mentioned raw materials is ground into powder successively, makes 47500 of the capsules of every 0.4g with prior art.
Embodiment 3
Get material by following proportioning:
5 kilograms of 3 kilograms of Semen Caesalpiniae Minaciss of Caulis Spatholobi
2 kilograms of 5 kilograms of Borneolum Syntheticums of Pulvis Fumi Carbonisatus
Above-mentioned raw materials is ground into powder successively, makes 50000 of the pills of every 0.3g with prior art.
Embodiment 4
Get material by following proportioning:
6 kilograms of 4 kilograms of Semen Caesalpiniae Minaciss of Caulis Spatholobi
3 kilograms of 4 kilograms of Borneolum Syntheticums of Pulvis Fumi Carbonisatus
After above-mentioned raw materials is ground into fine powder successively, as external-applied medicinal powder.
Embodiment 5
Get material by following proportioning:
3 kilograms of 5 kilograms of Semen Caesalpiniae Minaciss of Caulis Spatholobi
1 kilogram of 6 kilograms of Borneolum Syntheticum of Pulvis Fumi Carbonisatus
After above-mentioned raw materials is ground into powder successively, make ointment with prior art, external.
Table 1 upper respiratory tract infection treatment group and matched group personnel's ordinary circumstance (n=108)
| Project | Stomatitis (n=20) | Pharyngitis (n=30) | Tonsillitis (n=28) | Tracheitis (n=30) | ||||
| Treatment group (n=10) | Matched group (n=10) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=13) | Treatment group (n=15) | Matched group (n=15) | |
| Masculinity femininity 18-30 year 31-50 year 50-70 year | 6 4 3 3 4 | 5 5 4 2 4 | 8 12 6 10 4 | 5 5 4 4 2 | 10 5 8 4 3 | 8 5 7 3 3 | 7 8 5 5 5 | 8 7 6 6 3 |
Through X
2Check, two groups of ages, sex, state of an illness all have comparability (p＞0.05)
Table 2 alimentary canal inflammation treatment group and matched group personnel's ordinary circumstance (n=86)
| Project | Gastritis (n=30) | Cholecystitis (n=30) | Enteritis (n=26) | |||
| Treatment group (n=20) | Matched group (n=10) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=11) | |
| Masculinity femininity 18-30 year 31-50 year 50-70 year | 12 8 10 12 8 | 5 5 3 3 4 | 8 12 4 10 6 | 5 5 2 5 3 | 10 5 8 3 4 | 7 4 6 2 3 |
Through X
2Check, two groups of ages, sex, state of an illness all have comparability (p＞0.05)
Table 3 lower respiratory tract inflammation treatment group and matched group personnel's ordinary circumstance (n=115)
| Project | Cystitis (n=25) | Urethritis (n=30) | Prostatitis (n=30) | Pelvic inflammatory disease (n=30) | ||||
| Treatment group (n=15) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=15) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=15) | |
| Masculinity femininity 18-30 year 31-50 year 50-70 year | 6 9 2 8 5 | 6 4 2 4 4 | 7 8 6 6 3 | 8 7 7 5 3 | 20 4 6 10 | 10 2 3 5 | 15 8 5 2 | 15 7 6 2 |
Through X
2Check, two groups of ages, sex, state of an illness all have comparability (p＞0.05)
Table 4 scytitis treatment group and matched group personnel's ordinary circumstance (n=100)
| Project | Pruritus (n=20) | Dermatitis (n=30) | Tinea (n=30) | Herpes (n=20) | ||||
| Treatment group (n=10) | Matched group (n=10) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=15) | Treatment group (n=10) | Matched group (n=10) | |
| Masculinity femininity 18-30 year 31-50 year 50-70 year | 4 6 4 3 3 | 6 4 3 2 5 | 11 9 5 8 7 | 4 6 3 4 3 | 10 5 6 6 3 | 6 9 5 5 5 | 6 4 2 3 5 | 5 5 3 2 5 |
Through X
2Check, two groups of ages, sex, state of an illness all have comparability (p＞0.05)
Table 5 wound inflammation treatment group and matched group personnel's ordinary circumstance (n=88)
| Project | Scald (n=20) | Burn (n=20) | Knife injury hemorrhage (n=22) | Scratch wound infection (n=26) | ||||
| Treatment group (n=10) | Matched group (n=10) | Treatment group (n=10) | Matched group (n=10) | Treatment group (n=12) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=11) | |
| Masculinity femininity 18-30 year 31-50 year 50-70 year | 5 5 5 4 1 | 4 6 5 5 | 6 4 4 4 2 | 6 4 5 3 2 | 8 4 6 4 2 | 5 5 3 5 2 | 10 5 9 4 1 | 7 4 5 3 3 |
Through X
2Check, two groups of ages, sex, state of an illness all have comparability (p＞0.05)
Table 6, upper respiratory tract infection improve situation (108 example)
| Project | Stomatitis (n=20) | Pharyngitis (n=30) | Tonsillitis (n=28) | Tracheitis (n=30) | ||||
| Treatment group (n=10) | Matched group (n=10) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=13) | Treatment group (n=15) | Matched group (n=15) | |
| Produce effects enabledisable total effective rate | 3 5 2 80％ | 2 3 5 50％ | 8 11 1 95％ | 3 3 4 50％ | 5 8 1 93.3％ | 2 7 4 69.23％ | 4 9 2 86.66％ | 1 8 6 60％ |
Treatment group curative effect obviously is better than matched group ((p＞0.01))
Table 7, alimentary canal inflammation improve situation (86 example)
| Project | Gastritis (n=30) | Cholecystitis (n=30) | Enteritis (n=26) | |||
| Treatment group (n=20) | Matched group (n=10) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=11) | |
| Produce effects enabledisable total effective rate | 5 12 3 85％ | 2 5 3 70％ | 7 10 3 85％ | 3 3 4 60％ | 5 7 3 80％ | 2 5 4 63.63％ |
Treatment group curative effect obviously is better than matched group ((p＞0.01))
Table 8, lower respiratory tract inflammation are improved situation (115 example)
| Project | Cystitis (n=25) | Urethritis (n=30) | Prostatitis (n=30) | Pelvic inflammatory disease (n=30) | ||||
| Treatment group (n=15) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=15) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=15) | |
| Produce effects enabledisable total effective rate | 4 8 3 80％ | 2 4 4 60％ | 3 9 3 80％ | 3 7 5 67％ | 6 11 3 85％ | 2 4 4 60％ | 4 8 3 80％ | 3 7 5 60.66％ |
Treatment group curative effect obviously is better than matched group ((p＞0.01))
Table 9, scytitis improve situation (100 example)
| Project | Pruritus (n=20) | Dermatitis (n=30) | Tinea (n=30) | Herpes (n=20) | ||||
| Treatment group (n=10) | Matched group (n=10) | Treatment group (n=20) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=15) | Treatment group (n=10) | Matched group (n=10) | |
| Produce effects enabledisable total effective rate | 3 5 2 80％ | 2 3 5 50％ | 6 11 3 85％ | 3 3 4 60％ | 5 8 2 86.66％ | 3 7 5 66.66％ | 3 5 2 80％ | 1 5 4 60％ |
Treatment group curative effect obviously is better than matched group ((p＞0.01))
Table 10, wound inflammation are improved situation (88 example)
| Project | Scald (n=20) | Burn (n=20) | Knife injury hemorrhage (n=22) | Scratch wound infection (n=26) | ||||
| Treatment group (n=10) | Matched group (n=10) | Treatment group (n=10) | Matched group (n=10) | Treatment group (n=12) | Matched group (n=10) | Treatment group (n=15) | Matched group (n=11) | |
| Produce effects enabledisable total effective rate | 4 4 2 80％ | 2 3 5 50％ | 4 5 1 90％ | 3 3 4 50％ | 3 7 2 83.3％ | 2 5 3 70％ | 4 8 3 80％ | 1 6 4 63.6％ |
Treatment group curative effect obviously is better than matched group ((p＞0.01))
Claims (1)
1, a kind of anti-inflammation drugs is characterized in that being made up of following raw materials according:
Caulis Spatholobi 1-6 part
Semen Caesalpiniae Minacis 3-10 part
Pulvis Fumi Carbonisatus 2-8 part
Borneolum Syntheticum 1-3 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100487329A CN1325071C (en) | 2005-12-22 | 2005-12-22 | Antiphlogistic medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100487329A CN1325071C (en) | 2005-12-22 | 2005-12-22 | Antiphlogistic medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1823912A CN1823912A (en) | 2006-08-30 |
| CN1325071C true CN1325071C (en) | 2007-07-11 |
Family
ID=36934852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100487329A Expired - Fee Related CN1325071C (en) | 2005-12-22 | 2005-12-22 | Antiphlogistic medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1325071C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181310B (en) * | 2007-11-12 | 2010-10-13 | 黄永安 | Method for preparing Chinese medicine for curing empyrosis and medicament |
| CN103007229B (en) * | 2012-12-27 | 2013-11-27 | 陈淑香 | Medicine for treating neurogenic bladder |
| CN103690800B (en) * | 2014-01-13 | 2015-11-18 | 刘娟 | Pregnancy period vulval eczema nursing is loose and preparation method thereof |
| CN110772589A (en) * | 2019-08-02 | 2020-02-11 | 中国热带农业科学院热带作物品种资源研究所 | Baicao ointment with antibacterial, anti-inflammatory and antipruritic effects and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335171A (en) * | 2001-08-14 | 2002-02-13 | 孙玉洁 | Gynopathy treating Chinese medicine with functions of diminishing inflammation and eliminating spot and its prepn |
-
2005
- 2005-12-22 CN CNB2005100487329A patent/CN1325071C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335171A (en) * | 2001-08-14 | 2002-02-13 | 孙玉洁 | Gynopathy treating Chinese medicine with functions of diminishing inflammation and eliminating spot and its prepn |
Non-Patent Citations (3)
| Title |
|---|
| 中医外治法在妇科疾病的应用与展望 王雅松，中医药外治杂志，第13卷第1期 2004 * |
| 中医外治法在妇科疾病的应用与展望 王雅松，中医药外治杂志，第13卷第1期 2004;中医治疗小儿肺炎研究进展 安效先，中国中西医结合杂志，第14卷第12期 1994 * |
| 中医治疗小儿肺炎研究进展 安效先，中国中西医结合杂志，第14卷第12期 1994 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1823912A (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN101979041A (en) | Chinese medicinal preparation for treating various dermatoses | |
| CN1325071C (en) | Antiphlogistic medicine | |
| CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN102274355B (en) | Externally applied medicament for treating foot-and-mouth disease in pigs | |
| CN103301271A (en) | Tibetan medicine for treating pharyngitis and preparation method thereof | |
| CN103040928A (en) | Medicine for treating chronic eczema, dermatitis and keratoderma, as well as preparation method and application thereof | |
| CN101036732B (en) | Chinese medicine preparation for esophagus cancer and its compounding process | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN102058854B (en) | Chinese medicine for treating malignant lymphoma | |
| CN102357168B (en) | Chinese medicinal composition for treating gynecological diseases and preparation method thereof | |
| CN101279056B (en) | Children's antipyretic granule | |
| CN101077360B (en) | Medicinal composition for treating sugar diabetes skin ulcer and preparation method thereof | |
| CN101264305B (en) | Medicaments for treating no fever type common cold | |
| CN101254288A (en) | Applications of Chinese medicinal composition for curing colpitis medicament | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN104958613B (en) | Chinese medicine composition of malicious decomposed type decubital ulcer and preparation method thereof is accumulate in a kind for the treatment of | |
| CN104523942B (en) | One treats colpitic external preparation | |
| CN104383449B (en) | Pharmaceutical composition for treating depression syndrome | |
| CN101926859B (en) | Chinese medicinal composition | |
| CN103830679B (en) | A kind of medicine and application thereof for the treatment of irritable bowel syndrome | |
| CN102526248B (en) | Traditional Chinese medicine prescription capable of curing diabetes wound fester and continuously reducing blood sugar | |
| CN102274413A (en) | Chinese medicinal patch for treating infantile respiratory diseases | |
| CN106266285A (en) | A kind of sterilizing and itch-relieving, the external used medicine of heat-clearing and toxic substances removing | |
| CN101361805A (en) | Traditional Chinese medicine for treating mammary gland diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: PAN DINGFENG Free format text: FORMER OWNER: PAN ZHENGGUO Effective date: 20100827 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 679300 NO.13, YUNHAN LANE, PINGYUAN TOWN, YINGJIANG COUNTY, DEHONG STATE, YUNNAN PROVINCE TO: 679300 NO.10, YUNHAN LANE, YINGDONG ROAD, YINGJIANG COUNTY, DEHONG STATE, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100827 Address after: 679300, Yunnan Province, Dehong County, Yingjiang Province, East Road, admit rare Lane 10 Patentee after: Pan Dingfeng Address before: 679300, Yunnan, Dehong province Yingjiang County plain town No. 13 Patentee before: Pan Zhengguo |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070711 Termination date: 20181222 |